文献速递垂体与肾上腺疾病

sIL-2R:原发性肾上腺淋巴瘤的新型诊断生物标志物

sIL-2R: A Novel Diagnostic Biomarker for Primary Adrenal Lymphoma.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项前瞻性队列研究纳入2019至2021年一家三级医院的118例肾上腺肿块患者,评估血清可溶性白介素-2受体(sIL-2R)对原发性肾上腺淋巴瘤(PAL)的诊断价值。PAL患者sIL-2R和乳酸脱氢酶(LDH)水平均显著高于CT特征不确定和良性肾上腺肿块患者(均P<0.001)。sIL-2R区分PAL与其他肾上腺肿块的AUC为0.984(95%CI 0.95-1)和0.992(95%CI 0.975-1.000),按LDH类别调整后AUC提高至0.998(95%CI 0.994-1.000)和0.999(95%CI 0.996-1.000)。

要点

  • PAL患者血清sIL-2R水平显著高于CT特征不确定和良性肾上腺肿块患者(均P<0.001)。
  • PAL患者LDH水平亦显著高于CT特征不确定和良性肾上腺肿块患者(均P<0.001)。
  • sIL-2R诊断PAL的AUC为0.984/0.992,按LDH类别调整后提高至0.998/0.999。

核心结论

  • 首次发现血清sIL-2R及按LDH类别调整的sIL-2R水平对PAL具有良好诊断性能。

研究设计与样本

  • 前瞻性队列研究,纳入2019至2021年一家三级医院118例愿意检测血清sIL-2R水平的肾上腺肿块患者。

主要发现

  • PAL患者sIL-2R水平显著高于CT特征不确定和其他肾上腺肿块患者(均P<0.001)。
  • PAL患者LDH水平显著高于CT特征不确定和其他肾上腺肿块患者(均P<0.001)。
  • sIL-2R区分PAL与其他肾上腺肿块(PAL vs CT特征不确定的非PAL肾上腺肿块)的AUC为0.984(95%CI 0.95-1)。
  • sIL-2R区分PAL与其他肾上腺肿块(PAL vs 非PAL)的AUC为0.992(95%CI 0.975-1.000)。
  • 按LDH类别调整后AUC分别提高至0.998(95%CI 0.994-1.000)和0.999(95%CI 0.996-1.000)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Primary adrenal lymphoma (PAL) is difficult to distinguish from other adrenal masses. Soluble interleukin-2 receptor (sIL-2R) is a diagnostic biomarker for nodal non-Hodgkin lymphoma, whose association with PAL is unknown. OBJECTIVE: The aim of this study was to determine the diagnostic utility of serum sIL-2R for Patients with PAL. DESIGN: Prospective cohort study. SETTINGS AND PARTICIPANTS: A total of 118 patients with adrenal masses who were willing to be tested for levels of serum sIL-2R from a tertiary hospital between 2019 and 2021 were included. MAIN OUTCOMES AND MEASURES: Serum sIL-2R and lactate dehydrogenase (LDH) levels. RESULTS: Patients with PAL had significantly higher sIL-2R levels than those of patients with other adrenal masses with indetermined and benign computed tomography (CT) features (both Ps < 0.001). The LDH levels of patients with PAL were also significantly higher than those of patients with other adrenal masses with indeterminate and benign CT features (both Ps < 0.001). Good discrimination of patients with PAL from other patients (PAL vs other adrenal masses with indeterminate CT features/non-PAL) was achieved with an area under the receiver operating characteristic curve (AUC) of 0.984 (95% CI, 0.95-1)/0.992 (95% CI, 0.975-1.000) using the serum levels of sIL-2R and further improved (AUC = 0.998, 95% CI, 0.994-1.000; AUC = 0.999, 95% CI, 0.996-1.000) after adjusting by LDH category. CONCLUSIONS: For the first time, we have identified that serum sIL-2R and LDH category-adjusted sIL-2R levels have good diagnostic performances for PAL.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yu K, Xie W, Zhao L, et al. sIL-2R: A Novel Diagnostic Biomarker for Primary Adrenal Lymphoma. J Clin Endocrinol Metab. 2022. PMID: 35254444. doi:10.1210/clinem/dgac131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。